SCHEMBL301985

SCHEMBL301985

O=C(O)C1(c2cccc(Cl)c2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
AKR1C1 Q04828 2/20 0.53
AKR1C3 P42330 3/20 0.51
AKR1C2 P52895 3/20 0.51
CCR2 P41597 1/20 0.49
HSD11B1 P28845 1/20 0.47
APP P05067 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3110960 0.93 AKR1C1 (0.65) MEN1KMT2AAKR1C1AKR1C3AKR1C2
SCHEMBL9466663 0.93 AKR1C1 (0.59) MEN1KMT2AAKR1C1AKR1C3AKR1C2
Hydrochloric Acid SCHEMBL28595251 0.91 AKR1C1 (0.62) MEN1KMT2AAKR1C1AKR1C3AKR1C2
SCHEMBL4827909 0.91 AKR1C1 (0.62) MEN1KMT2AAKR1C1AKR1C3AKR1C2
SCHEMBL1627025 0.89 MEN1 (0.50) MEN1KMT2AAKR1C1AKR1C3AKR1C2
SCHEMBL11094391 0.89 KCNA3 (0.51) MEN1KMT2AAKR1C1AKR1C3AKR1C2
SCHEMBL28618128 0.87 CCR2 (0.47) MEN1KMT2ACCR2HSD11B1SLC6A4
SCHEMBL4833194 0.85 HSD11B1 (0.47) MEN1KMT2ACCR2HSD11B1SLC6A4
SCHEMBL12002886 0.84 PARP1 (0.47) MEN1KMT2ACCR2HSD11B1SLC6A4
SCHEMBL20329719 0.84 CCR2 (0.48) MEN1KMT2ACCR2HSD11B1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039482-A1 SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-02-14 US claimed
WO-2007147574-A1 SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-27 WO claimed
EP-1870416-A1 Sulphonamido-macrocycles as tie2 inhibitors Bayer Schering Pharma Aktiengesellschaft (DE) 2007-12-26 EP claimed
US-7063856-B2 Pharmaceutical composition containing aminocetonitrile compounds and the use thereof for the preparation of a pharmaceutical composition for the treatment of endoparasitic pests in animals NOVARTIS ANIMAL HEALTH US, INC. (US) 2006-06-20 US claimed
EP-4587433-A1 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS Takeda Pharmaceutical Company Limited (JP) 2025-07-23 EP disclosed
WO-2025074305-A1 N-(1-(AMINOMETHYL)CYCLOPROPYL)(ARYL OR HETEROARYL) CARBOXAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-04-10 WO disclosed
US-12239630-B2 Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-03-04 US disclosed
CN-115068468-B Carboxylic aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2025-02-25 CN disclosed
WO-2025011610-A1 AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-01-16 WO disclosed
CN-119306790-A Amide derivative, composition and use thereof 深圳市塔吉瑞生物医药有限公司 2025-01-14 CN disclosed
US-20240382482-A1 PLASMA KALLIKREIN INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2024-11-21 US disclosed
CN-115137726-B Carboxylic aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2024-08-13 CN disclosed
EP-2134692-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION Wyeth a Corporation of the State of Delaware (US) 2009-12-23 EP disclosed
EP-2097410-A1 HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS Green Cross Corporation (KR) 2009-09-09 EP disclosed
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins WYETH (US) 2008-10-16 US disclosed
WO-2008121817-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION WYETH (US) 2008-10-09 WO disclosed
US-20080081812-A1 Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists GREEN CROSS CORPORATION (KR) 2008-04-03 US disclosed
WO-2008039023-A1 HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS GREEN CROSS CORPORATION (KR) 2008-04-03 WO disclosed
US-20080039482-A1 SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-02-14 US disclosed
EP-1870416-A1 Sulphonamido-macrocycles as tie2 inhibitors Bayer Schering Pharma Aktiengesellschaft (DE) 2007-12-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039482-A1 SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME TIE1, KDR, TEK MEN1 286/4885KMT2A 522/4885AKR1C1 962/4885
US-12239630-B2 Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor BDKRB1, BDKRB2, HCAR1 MEN1 875/4885KMT2A 2537/4885AKR1C1 132/4885
US-20240382482-A1 PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 MEN1 662/4885KMT2A 1570/4885AKR1C1 194/4885
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins VCAM1, ICAM1, SELE MEN1 4659/4885KMT2A 3971/4885AKR1C1 2640/4885
US-20080081812-A1 Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists CNR2, CNR1, GPR119 MEN1 3855/4885KMT2A 2129/4885AKR1C1 1364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.